(ANSA) - The AJA, 11 MAR - The EMA has stated that the anti-Covid vaccine from AstraZeneca can continue to be used, unexpected investigations on blood clots.
EMA, a statement read, "is aware that the Danish Health Authority has suspended its vaccination campaign with AstraZeneca. This was decided as a precautionary measure while a full investigation into reports of blood clots in people who received the vaccine, including a case in Denmark where a person died. Some other Member States have also stopped vaccinating with this vaccine. "
At the same time, adds the European Medicines Agency, "there are currently no indications that vaccination has caused these diseases, which are not listed as side effects with this vaccine. The position of the EMA Safety Committee (PRAC) is that benefits of the vaccine continue to outweigh its risks and the vaccine can continue to be administered while investigations into cases of thromboembolic events are ongoing. "
"The number of thromboembolic events in vaccinated people does not exceed the number observed in the population. As of 10 March 2021, 30 cases of thromboembolic events have been reported among nearly 5 million people vaccinated with the Covid-19 AstraZeneca vaccine in the European Economic Area."
(HANDLE).